Ziauddin1 , Inayat Ullah1 , Shah Zeb2 , Shahabuddin Zia3 , Dawood Khan1 and Muhammad Abbas2

Abstract

Objective:To see the result of combination of Sofosburvir and Daclatsvir in the treatment of Hepatitis C Genotype 2 and Genotype 3.

Study Design: Observational intent-to-treat study.

Place and Duration of Study: This study was conducted at the Department of Medicine, Lady Reading Hospital, Peshawar from January 2020 to December 2020.

Materials and Methods: 172 HCV patients i.e., HCV genotype 2 and genotype 3were included. Qualitative PCR including genotyping were done for all these patients. Liver status was evaluated through ultrasound. All patients were given combination of Sofosbuvir 400mg OD and Daclatasvir 60mg OD ± Ribavirin 400mg TDS. SVR was obtained at 12 weeks. Data was analyzed by SPSS version 22.

Results: Among 172 patients, 76 (44.2%) were males and 96 (55.8%) were females. The mean age was 40.84 years ± 12.0 SD. In these patients, 52(30.2%) patients and 120 (69.8%) were HCV genotype 2 and genotype 2 respectively. Among these patients, 86.1% of patients with HCV genotype 3 and 84.1% of HCV genotype 2 patients achieved SVR at 12 weeks. Sixty percent of the cirrhotic patients and 91.2% of those patients who had previously experienced treatment, obtained SVR at 12 weeks. Ninety-two percent male patients and 94.8% of female patients obtained SVR at 12 weeks.

Conclusion: Combination of Daclatasvir and Sofosbuvir with or without Ribavirin (DCV+SOF±RBV) have impressive results in achieving SVR at week 12 while treating HCV genotype 2,3.

Key Words:Chronic HCV, genotype 3, genotype 2, Sofosbuvir, Daclatasvir.

Citation of article: Ziauddin, Inayat Ullah, Zeb S, Zia S, Khan D, Abbas M. Combination of Sofosburvir and Daclatsvir in the treatment of Hepatitis C Genotype 2 And Genotype 3. Med Forum 2021;32(4):20-23.